KOD · Kodiak Sciences Inc.
$42.64
+1.39 (+3.37%)
At close · Jul 17
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our financial condition raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$2.67B
Shares
62,578,441
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.64
Open$40.65
Day$39.44–44.13
52W$4.60–47.84
Avg vol 30d839K
Short int10.6M · 17.0% float · 10.3d
Short vol65%
Last earningsNov 13, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+47%
above
Price vs 50-day avg
+15%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+65%
trailing
YTD return
+53%
this year
Relative strength
+57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $37 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
10 of 190 funds reported for Jun 30 · net +23.5K sh shares · +2 new
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Rising
16.98% of float · ▲ +1.4% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
EPS growth
−29%
Y/Y
Free cash flow
$-136.5M
Balance sheet
$209.9M
net cash
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+47%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $37 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
10 of 190 funds reported for Jun 30 · net +23.5K sh shares · +2 new
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Rising
16.98% of float · ▲ +1.4% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $43 · 88%
52-wk high $48
vs 200-day avg +47%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KOD
this stock
Kodiak Sciences Inc.
|
$2.67B | +52.5% | — | — | 17.0% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KOD | +3.2% | +19.4% | +64.9% | +9.5% | +52.5% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | +4.8% | +19.1% | +57.1% | +9.9% | +43.5% |